AstraZeneca Casodex
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SNDA withdrawn Dec. 19 for 150 mg bicalutamide for treatment of locally advanced, non-metastatic lung cancer. The company expects to refile in 2001